Ovid Therapeutics (NASDAQ:OVID) Research Coverage Started at Lifesci Capital

Lifesci Capital started coverage on shares of Ovid Therapeutics (NASDAQ:OVID) in a research report sent to investors on Monday, MarketBeat Ratings reports. The firm issued an outperform rating and a $4.00 price target on the stock. Lifesci Capital also issued estimates for Ovid Therapeutics’ Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.46) EPS, Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.11) EPS and FY2026 earnings at ($0.38) EPS.

A number of other analysts have also recently commented on OVID. Leerink Partners initiated coverage on Ovid Therapeutics in a research report on Monday, November 17th. They set an “outperform” rating and a $5.00 price objective for the company. Oppenheimer assumed coverage on shares of Ovid Therapeutics in a report on Thursday, October 9th. They set an “outperform” rating and a $7.00 price target for the company. Roth Capital started coverage on shares of Ovid Therapeutics in a research report on Thursday, December 11th. They issued a “buy” rating and a $3.00 price objective for the company. B. Riley restated a “buy” rating on shares of Ovid Therapeutics in a research report on Friday, October 10th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $2.00 target price on shares of Ovid Therapeutics in a research note on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $3.88.

Ovid Therapeutics Trading Down 1.4%

Shares of OVID opened at $1.79 on Monday. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.24 and a quick ratio of 4.24. Ovid Therapeutics has a 1-year low of $0.24 and a 1-year high of $2.01. The stock has a market cap of $127.11 million, a price-to-earnings ratio of -3.57 and a beta of 0.04. The firm has a 50 day simple moving average of $1.51 and a 200-day simple moving average of $1.09.

Ovid Therapeutics (NASDAQ:OVID) last announced its earnings results on Wednesday, November 12th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The company had revenue of $0.13 million for the quarter, compared to analyst estimates of $0.17 million. Ovid Therapeutics had a negative net margin of 550.04% and a negative return on equity of 63.79%. Equities analysts forecast that Ovid Therapeutics will post -0.4 EPS for the current fiscal year.

Institutional Trading of Ovid Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Private Advisor Group LLC acquired a new stake in Ovid Therapeutics during the 3rd quarter valued at $33,000. Apollon Wealth Management LLC acquired a new position in shares of Ovid Therapeutics during the third quarter valued at $36,000. Nuveen LLC bought a new position in shares of Ovid Therapeutics during the first quarter worth about $37,000. Jane Street Group LLC acquired a new stake in shares of Ovid Therapeutics in the 2nd quarter worth about $47,000. Finally, Velan Capital Investment Management LP increased its holdings in shares of Ovid Therapeutics by 64.9% in the 2nd quarter. Velan Capital Investment Management LP now owns 160,000 shares of the company’s stock worth $53,000 after acquiring an additional 63,000 shares during the period. 72.24% of the stock is currently owned by institutional investors and hedge funds.

More Ovid Therapeutics News

Here are the key news stories impacting Ovid Therapeutics this week:

• Positive Sentiment: LifeSci Capital initiated coverage with an “Outperform” rating and a $4.00 price target, publishing detailed quarterly and FY EPS forecasts that show improving (but still negative) losses through FY2026 — this institutional initiation and multi-quarter model give the stock a visible analyst catalyst. LifeSci Capital initiates coverage of Ovid Therapeutics (OVID) with outperform recommendation
• Positive Sentiment: HC Wainwright & Co. reiterated a buy recommendation, reinforcing sell-side support that could help sustain investor interest and trading momentum. HC Wainwright & Co. reiterates Ovid Therapeutics (OVID) buy recommendation
• Neutral Sentiment: LifeSci’s published model projects ongoing negative EPS (examples: FY2025 ~($0.46), FY2026 ~($0.38), quarterly EPS in the ~$0.08–$0.11 loss range) — the estimates provide a roadmap for expected cash burn and timing for any positive financial inflection, but they are not evidence of immediate revenue improvement.
• Neutral Sentiment: A December short-interest report shows an apparent large “increase” but lists zero shares and a 0.0 days-to-cover figure — this looks like a data glitch and shouldn’t be treated as a meaningful change in sentiment until corrected or clarified by exchanges/brokers.

About Ovid Therapeutics

Ovid Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, the company applies a precision medicine approach to target underlying mechanisms of disease in patients with genetic conditions affecting the central nervous system. Its research platform centers on small-molecule modulators of neurotransmitter pathways to restore neural network function in disorders with high unmet medical need.

The company’s lead development candidate, OV101 (gaboxadol), is a selective extrasynaptic GABAA receptor agonist being investigated for the treatment of Angelman syndrome and Fragile X syndrome.